The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

Until now, OSA treatment has focused on mechanical support during sleep in the form of positive airway ... option for certain patients with obstructive sleep apnea," said Sally Seymour, MD ...

From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...

The most common form of sleep apnea is obstructive sleep apnea (OSA), which affects nearly a billion people worldwide. It occurs due to a blockage in the upper airway that hinders breathing during ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA ... System ® Short Form Sleep-Related Impairment ...

Obstructive Sleep Apnea (OSA): Caused by a physical blockage ... This is the most common form and seen predominantly in obese individuals. 2. Central Sleep Apnea (CSA): Occurs when the brain ...

Currently, obstructive sleep apnea is managed with PAP, or positive airway pressure, machines, which gently blow air into the ...

With regular checkups every three to six months, we form trusted relationships ... a condition frequently linked to obstructive sleep apnea. Studies reveal a strong connection between teeth ...